CRISPR/Cas9 for hepatitis B virus infection treatment
Abstract Hepatitis B virus (HBV) infection remains a global health challenge. Despite the availability of effective preventive vaccines, millions of people are at risk of cirrhosis and hepatocellular carcinoma. Current drug therapies inhibit viral replication, slow the progression of liver fibrosis...
Main Authors: | Bo Cai, Shixue Chang, Yuhan Tian, Shuai Zhen |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2023-05-01
|
Series: | Immunity, Inflammation and Disease |
Subjects: | |
Online Access: | https://doi.org/10.1002/iid3.866 |
Similar Items
-
Current Status and Challenges in Anti-Hepatitis B Virus Agents Based on Inactivation/Inhibition or Elimination of Hepatitis B Virus Covalently Closed Circular DNA
by: An-Qi Zhuang, et al.
Published: (2023-11-01) -
Improved Specificity and Safety of Anti-Hepatitis B Virus TALENs Using Obligate Heterodimeric <i>Fok</i>I Nuclease Domains
by: Tiffany Smith, et al.
Published: (2021-07-01) -
Depleting hepatitis B virus relaxed circular DNA is necessary for resolution of infection by CRISPR-Cas9
by: Dmitry Kostyushev, et al.
Published: (2023-03-01) -
Role of epigenetic modification in interferon treatment of hepatitis B virus infection
by: Zhijing Yang, et al.
Published: (2022-10-01) -
Evaluation of the HBV liver reservoir with fine needle aspirates
by: Barbara Testoni, et al.
Published: (2023-10-01)